Led by Selangor, Malaysia is becoming a regional powerhouse in life sciences
Malaysia has established itself as Southeast Asia’s premier life sciences hub, supported by robust government backing, a strong manufacturing base, and advanced research capabilities. The sector encompasses medical devices, pharmaceuticals, and biotechnology, with Selangor serving as a primary centre of activity.
The largest medical device manufacturing hub in Southeast Asia
In 2024, Malaysia’s medical device exports surged by 31% to US$9 billion, buoyed by US$5 billion in approved investments between 2021 and 2024. As one of the global offshore manufacturing hubs for medical devices, Malaysia hosts over 200 medical device manufacturers, including one third of the top 30 global companies. An established manufacturing base, Selangor is home to major manufacturers of medical gloves, single-use disposables, orthopaedic implants, surgical instruments, and other medical equipment. With its mature ecosystem and integrated M&E value chain supporting the medical device industry, Selangor is well-positioned to become a premier investment destination for medical device production.
Strong pharmaceutical manufacturing and R&D
The pharmaceutical industry in Malaysia comprises nearly 300 licensed manufacturers producing traditional medicines and health supplements, pharmaceutical products, and veterinary products. Selangor hosts a significant concentration of pharmaceutical companies across key nodes in Shah Alam, Petaling Jaya, and Bangi. The state offers an end-to-end pharmaceutical value chain, supporting innovation across biopharmaceuticals, generic drugs, nutraceuticals, and traditional and complementary medicines. Selangor’s research strength is exemplified by a robust clinical research ecosystem, anchored by the Ministry of Health’s (MOH’s) Institute for Clinical Research (ICR) in Shah Alam and the Clinical Research Centre network comprising six public hospitals in the state. This positions Selangor as an attractive destination for clinical product development and trials.
Advancing biotechnology innovation in the region
Malaysia drives regional biotechnology leadership through the National Biotechnology Policy 2.0, supporting innovation across agriculture, healthcare, and bio-industrial applications. The BioNexus Status and Bio-based Accelerator Programme (BBA) facilitate both local and international biotech development. Selangor serves as a key biotechnology hub through the Selangor Biotechnology Action Plan 2021-2030, which combines established pharmaceutical infrastructure, skilled talent, and a strategic location to offer biotech companies access to Southeast Asian markets.